A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab

Abstract

Chemotherapy, radiation therapy, surgery, and other treatments have proven to be ineffective for a patient suffering with metastatic melanoma. Recently, immunotherapy has become a potential method for treating the condition. Combination therapy, which focuses on various immune system components, has grabbed the attention of the scientific world. The treatment of metastatic melanoma with the immune checkpoint inhibitors Ipilimumab and Nivolumab has been demonstrated to be very successful. This review aims to analyze the current literature and articles from PubMed and Google Scholar and ClinicalTrials.gov on the use of Ipilimumab and Nivolumab in treating metastatic melanoma. Moreover, this work focuses at some clinical trial results for this combination therapy. The findings demonstrate that Ipilimumab and Nivolumab combination therapy substantially increases patient survival. In conclusion, Ipilimumab and Nivolumab in combination is a very promising treatment for metastatic melanoma. However, there are several clinical and practical issues that must be resolved to maximize the effectiveness of this combination therapy more research in the field is required.